Burden Changes in Notifiable Infectious Diseases in Taiwan During the COVID-19 Pandemic

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2024 Sep 13

PMID 39267943

Authors

Ying-Fei Yang

Yu-Miao Chen

Si-Yu Chen

Po-Hao Chiu

Szu-Chieh Chen

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to assess the impact of the COVID-19 pandemic on the disease burden of Taiwan's notifiable infectious diseases (NIDs). We compared disease burdens between the pandemic and pre-pandemic year of 2020 (with non-pharmaceutical interventions (NPIs)) and 2010 (without NPIs), respectively, to understand the overall pandemic impact on NIDs in Taiwan.

Methods: Forty-three national NIDs were analyzed using the Statistics of Communicable Diseases and Surveillance Report by estimating the premature death and disability different transmission categories, sex, and age groups. The study evaluated the impact of diseases by assessing the years lost due to death (YLLs), the duration of living with disability (YLDs), and the overall disability-adjusted life years (DALYs) by measuring both the severity of the illness and its duration.

Results: Taiwan recorded 1,577 (2010) and 1,260 (2020) DALYs per million population and lost 43 NIDs, decreasing 317 DALYs per million population. Tuberculosis, HIV/AIDS and acute hepatitis B/D were the leading causes of DALYs, accounting for 89% (2010) and 77% (2020).

Conclusion: Overall, this study provided the first insight of changes in disease burdens in NIDs between pre- and post-COVID-19 based on a nationwide viewpoint for further preventive measures and interventions to be focused on specific diseases by associated health administrations and policies.

References

Masresha B, Biresaw H, Moyehodie Y, Mulugeta S . Time-to-Disability Determinants Among Leprosy Patients Enrolled for Treatment at ALERT Center, Addis Ababa, Ethiopia: A Survival Analysis. Infect Drug Resist. 2022; 15:2729-2741. PMC: 9166622. DOI: 10.2147/IDR.S361799. View

Lucchini L, Centellegher S, Pappalardo L, Gallotti R, Privitera F, Lepri B . Living in a pandemic: changes in mobility routines, social activity and adherence to COVID-19 protective measures. Sci Rep. 2021; 11(1):24452. PMC: 8712525. DOI: 10.1038/s41598-021-04139-1. View

Chen A, Chu I, Yeh M, Chen Y, Lee C, Lin H . Differentiating impacts of non-pharmaceutical interventions on non-coronavirus disease-2019 respiratory viral infections: Hospital-based retrospective observational study in Taiwan. Influenza Other Respir Viruses. 2021; 15(4):478-487. PMC: 8189242. DOI: 10.1111/irv.12858. View

Birnie E, Virk H, Savelkoel J, Spijker R, Bertherat E, Dance D . Global burden of melioidosis in 2015: a systematic review and data synthesis. Lancet Infect Dis. 2019; 19(8):892-902. PMC: 6867904. DOI: 10.1016/S1473-3099(19)30157-4. View

Ock M, Park B, Park H, Oh I, Yoon S, Cho B . Disability Weights Measurement for 289 Causes of Disease Considering Disease Severity in Korea. J Korean Med Sci. 2019; 34(Suppl 1):e60. PMC: 6434154. DOI: 10.3346/jkms.2019.34.e60. View

Lee K, Lai C, Chao C, Tang H . Increase in sexually transmitted infection during the COVID-19 pandemic in Taiwan. J Eur Acad Dermatol Venereol. 2020; 35(3):e171-e172. DOI: 10.1111/jdv.17005. View

Hirae K, Hoshina T, Koga H . Impact of the COVID-19 pandemic on the epidemiology of other communicable diseases in Japan. Int J Infect Dis. 2023; 128:265-271. PMC: 9837205. DOI: 10.1016/j.ijid.2023.01.013. View

Vodicka E, Zimmermann M, Lopez A, Silva M, Gorgolon L, Kohei T . Japanese encephalitis vaccination in the Philippines: A cost-effectiveness analysis comparing alternative delivery strategies. Vaccine. 2020; 38(13):2833-2840. PMC: 7068699. DOI: 10.1016/j.vaccine.2020.02.018. View

Geng M, Zhang H, Yu L, Lv C, Wang T, Che T . Changes in notifiable infectious disease incidence in China during the COVID-19 pandemic. Nat Commun. 2021; 12(1):6923. PMC: 8626444. DOI: 10.1038/s41467-021-27292-7. View

10.

Lai C, Yu W . The COVID-19 pandemic and tuberculosis in Taiwan. J Infect. 2020; 81(2):e159-e161. PMC: 7286835. DOI: 10.1016/j.jinf.2020.06.014. View

11.

Hibiya K, Iwata H, Kinjo T, Shinzato A, Tateyama M, Ueda S . Incidence of common infectious diseases in Japan during the COVID-19 pandemic. PLoS One. 2022; 17(1):e0261332. PMC: 8754328. DOI: 10.1371/journal.pone.0261332. View

12.

Knoll M, Wonodi C . Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2020; 397(10269):72-74. PMC: 7832220. DOI: 10.1016/S0140-6736(20)32623-4. View

13.

Ullrich A, Schranz M, Rexroth U, Hamouda O, Schaade L, Diercke M . Impact of the COVID-19 pandemic and associated non-pharmaceutical interventions on other notifiable infectious diseases in Germany: An analysis of national surveillance data during week 1-2016 - week 32-2020. Lancet Reg Health Eur. 2021; 6:100103. PMC: 8454829. DOI: 10.1016/j.lanepe.2021.100103. View

14.

Lai C, Chen S, Yen M, Lee P, Ko W, Hsueh P . The impact of the coronavirus disease 2019 epidemic on notifiable infectious diseases in Taiwan: A database analysis. Travel Med Infect Dis. 2021; 40:101997. PMC: 7905388. DOI: 10.1016/j.tmaid.2021.101997. View

15.

Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D . Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10318):2258-2276. PMC: 8639161. DOI: 10.1016/S0140-6736(21)02717-3. View

16.

. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(9995):743-800. PMC: 4561509. DOI: 10.1016/S0140-6736(15)60692-4. View

17.

Lai C, Lee P, Hsueh P . How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020-2022. J Microbiol Immunol Infect. 2023; 56(3):433-441. PMC: 10079311. DOI: 10.1016/j.jmii.2023.04.001. View

18.

Cuschieri S, Calleja N, Devleesschauwer B, Wyper G . Estimating the direct Covid-19 disability-adjusted life years impact on the Malta population for the first full year. BMC Public Health. 2021; 21(1):1827. PMC: 8501913. DOI: 10.1186/s12889-021-11893-4. View

19.

Baker R, Saad-Roy C, Park S, Farrar J, Metcalf C, Grenfell B . Long-term benefits of nonpharmaceutical interventions for endemic infections are shaped by respiratory pathogen dynamics. Proc Natl Acad Sci U S A. 2022; 119(49):e2208895119. PMC: 9894244. DOI: 10.1073/pnas.2208895119. View

20.

Chen L, Wang L, Xing Y, Xie J, Su B, Geng M . Persistence and Variation of the Indirect Effects of COVID-19 Restrictions on the Spectrum of Notifiable Infectious Diseases in China: Analysis of National Surveillance Among Children and Adolescents From 2018 to 2021. JMIR Public Health Surveill. 2024; 10():e47626. PMC: 11137434. DOI: 10.2196/47626. View